AgBioResearchers Question Effectiveness of Warning Labels on OTC Drugs
Medicine packages barrage consumers with information, some required to be “prominent” and “conspicuous.” But marketing claims and brand names still overshadow critical fine print on non-prescription medications, MAES researchers found.
In a study published in the March 30 Proceedings of the National Academies of Science, MAES researchers examined the effectiveness of two required warnings on over-the-counter medications, specifically their relative prominence and conspicuousness.
“We wanted to be able to quantify how well warning statements in over-the-counter drug packaging were working to convey information to consumers,” explained Laura Bix, MAES packaging researcher and lead author. “To be effective, warnings about the lack of a child resistant feature, or those that alert consumers to potential tampering of the product, need to be read and comprehended at the time of purchase.”
Medicine labels carry brand identification and descriptions of contents; quantity; price; ingredients; dosage; directions; barcodes; and warning statements. Federal regulations require packages that do not have a child resistant feature, for example, to conspicuously state that the product is not intended for homes with small children. Such packages are blamed by the Consumer Product Safety Commission for a number of child poisonings every year.
Bix and her colleagues quantified the relative prominence and conspicuousness of five different label elements on the packages of OTC pain-killers: the tamper-evident warning; the child-resistant warning; the brand name; the drug facts information; and statement of claims such as “extra strength.” They also evaluated how well test subjects remembered information presented on the product packaging.
Using an eye tracking device, the researchers found that people spent the most time looking at the brand of the product and significantly less time looking at the tamper-evident and child-resistant warnings. Study participants also recalled the brand of the products at a higher rate. While two-thirds recalled one or more brands that they viewed during the course of the study, only 18 percent recalled warnings related to alcohol and 8.2 percent recalled that the product was not to be used in households with young children. Not one recalled warnings about tamper-evident features.
The researchers also found that the brand and product claims were significantly more legible than the warning statements. They noted that the higher legibility of the brand name wasnt surprising, given the importance of brand identification in purchasing decisions.
“Little specific guidance exists from the federal government regarding what it means to be ‘prominent’ or ‘conspicuous,’ yet, this term is used quite frequently in the regulations that dictate labeling for a variety of product,” Bix said. “Our findings call into question whether or not these warnings are working, but do not indicate why. An array of reasons should be investigated: these could include design and graphics, consumer experience and previous knowledge and whether or not consumers recognize the potential consequences of missing or disregarding this information.”
“Finding effective ways to get people to read and heed warnings on over-the-counter drugs is critical to their safety and well-being as well as those around them—especially children,” MAES Director Steve Pueppke said. “This research is an important step toward using consumer-focused science to improve design and labeling elements for these medications.”
Follow-up research being conducted by one of Bixs graduate students, Raghav Prashant Sundar, is looking at the same noticeability, recall and legibility issues for prescription drugs bearing prescription warning labels—the colorful stickers often applied at the pharmacy.
Bix’s study is available online at the Proceedings of the National Academies of Science website.
In addition to Bix, other MAES scientists involved in the research are Rafael Auras, MAES packaging scientist, and Maria Lapinski-Lafaive, MAES risk communication scientist.
Click to subscribe to our e-publications:Subscribe